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Aim: We intended to establish the threshold of Anti-Mullerian Hormone (AMH) for detection of Ovarian
Hyper-Stimulation Syndrome (OHSS) and poor response to treatment in Iranian infertile women.
Methods: Pre-stimulation menstrual cycle day-3 hormonal indices including basal AMH values were measured in
105 infertile women aged 32.5 ± 4.3 years. Patients underwent long GnRH agonist Controlled Ovarian Hyperstimulation
(COH) in a referral infertility center (Tehran, Iran). The gonadotropin dose was determined based on the age and basal
serum Follicular Stimulating Hormone (FSH) level. The IVF/ICSI cycles were followed and the clinical and sonographic
data were recorded.
Results: Sixteen cases developed OHSS. The prevalence of PCOS was higher in subjects with OHSS [62.5 %
(38.8-86.2) vs. 17 % (9.2-24.9)]. The patients with OHSS had higher ovarian follicular count [23.7 (3.2) vs. 9.1 (0.5);
p < 0.05], collected oocytes [13.5 (1.9) vs. 6.9 (0.5); p < 0.05] and AMH level [7.9 (0.7) vs. 3.6 (0.3); p < 0.05]. Basal
AMH level and oocyte yields (but not age, BMI, and PCOS) correlated with occurrence of OHSS; and only the AMH
levels were associated with poor ovarian response (oocytes yield ≤ 4). The optimal cutoff value for the prediction
of OHSS was 6.95 ng/ml (area under the receiver operating characteristics curve: 0.86; CI: 0.78-0.95; sensitivity: 75 %;
specificity: 84 %; odds ratio for occurrence of OHSS: 9 and p < 0.001). The optimal cut point to discriminate poor
response (oocytes ≤4) was 1.65 ng/ml ( AUC : 0.8; CI: 0.69-0.91; sensitivity: 89 % specificity : 71 %; and OR = 23.8
and P value <0.001).
Conclusions: Iranian women with basal AMH level > 6.95 ng/ml are at high risk of developing OHSS and those
with AMH level < 1.65 ng/ml are poor responders.
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Anti-Mullerian Hormone (AMH) is a granulosa cell
derived hormone secreted from pre-antral and small an-
tral follicles. AMH substantially inhibits the initiation of
primordial follicle growth and contributes to normal
folliculogenesis by enhancing the role of FSH in cyclic
recruitment of follicles [1]. Clinically, AMH can serve as
a reliable ovarian reserve marker [2] independent of go-
nadotropins levels [3]. A particularly helpful aspect of
AMH, when used as an ovarian reserve marker, is that
its serum levels remain relatively constant during normal
menstrual cycles [4–6]. The reported variability during
the menstrual cycles is not possibly clinically influential
[7]. In 2002, Seifer et al. underscored the association of
AMH levels with ovarian response to Controlled Ovar-
ian Hyperstimulation (COH) [8]. The recent meta-
analysis by Broer et al. highlighted 9 studies employing
AMH to predict excessive responses during COH [9].
While the ability to predict excessive ovarian stimulation
using basal AMH values is established, the optimal
threshold of AMH to predict Ovarian Hyper-Stimulation
Syndrome (OHSS) is controversial and subjected to this
research.
Methods
A total of 105 infertile couples undergoing COH enrolled
in this study. They were visited in a private referral infer-
tility center (Tehran, Iran) between March 2010 and
February 2011. Subjects with any known systemic diseases
or endocrine disorders including diabetes, hypothy-
roidism, hyper-prolactinemia, and those who were receiv-
ing levothyroxine or cabergoline were excluded. Data of
the first attempt was recorded for the patients who under-
went more than one IVF/ICSI cycle. The corresponding
demographic and infertility related data of the participants
were collected and the baseline pre-stimulation AMH,
FSH, LH, testosterone, dehydroepiandrosterone sulfate,
TSH, and prolactin plasma levels were measured on the
third day of the previous menstrual cycle. Pre-stimulation
cycle(s) was/were induced in those without regular men-
ses with intramuscular injection of 100 mg progestron in
oil (Iran Hormone, Tehran, Iran) and maintained with
daily OCP from day 3 in those without history of regular
menses after withdrawal bleed. Serum AMH was mea-
sured using ultrasensitive ELISA (Beckman-Coulter
Ireland, Inc., Galway, Ireland) with functional sensitivity of
0.2 ng/ml and intra and inter-assay coefficient of variabil-
ity of 8 and 12 %, respectively. Samples were centrifuged
and the assays were done in serums after performing cali-
brations according to the manufacturer instructions.
Samling of the hemolyzed samples were repeated and no
particular strategy for handling Heterophile antibody was
employed. The chief gynecologist of the center (i.e.
MMA) selected the stimulation protocol, type, and doseof the gonadotropin and diagnosed and managed OHSS
irrespective of patients’ participation in the study. The fol-
licle count (≥14 mm) based on sonographic examination
on the day of HCG administration, the number of re-
trieved oocytes, and the final outcome of the IVF/ICSI
cycle were recorded.
Controlled ovarian hyperstimulation protocol
Participants were recruited among those who underwent
long GnRH agonist protocol irrespective of age, gonado-
tropin dosage, and history of OHSS or antral follicular
count. From day 21 of the pre-stimulation menstrual
cycle, the patient received a daily subcutaneous injection
of Boucerelin acetate (Superfact, Hoecht AG, Frankfurt,
Germany). The gonadotropin (GonalF, Serono, Switzerland)
was added on day 2 or 3 of the IVF/ICSI cycle. Dosing
was determined by the chief treating gynecologist of the
center mainly based on the age and basal FSH levels
(ranged between 150 and 225 IU/day). Dosage of gonado-
tropin was adjusted based on the degree of ovarian re-
sponse in interval sonographic examinations (data not
collected for this report). Patients were examined by daily
trans-vaginal sonography starting on day 7 of stimulation.
HCG (250 mgr; Ovitrelle, Merck, Serono) was injec-
ted subcutaneously when the sonographic examination
showed a minimum of two 18 mm follicles. Oocyte
pickup was performed from posterior vaginal fornix
34 to 36 hours after HCG administration. Embryo
was transferred within 2 days of oocyte pickup and
the patient received 400 mg of cyclogest (Alpharma,
Barnstaple, UK) every 12 hours during the first
12 weeks of gestation and 2 mg of estradiol valereate
every 12 hours for 2 weeks. Serum βHCG was mea-
sured 15 days after embryo transfer. Biochemical
pregnancy was defined as βHCG value > 50 mIU/ml.
Sonographic examination was performed 2 weeks later
to confirm the presence of gestational Sac and then
2 weeks afterward to confirm viability of the embryo.
The OHSS related symptoms and signs, including
abdominal distension and discomfort, nausea, vomiting,
diarrhea, ascites, plural effusion, edema, oliguria, hyper-
coagulative state, serum creatinine of 1.0-1.5 mg/ml,
hemoconcentration, and electrolyte imbalance were moni-
tored. Suspected OHSS cases were examined by sonog-
raphy to determine ovarian enlargement and ascites [10].
OHSS and the severity of the condition were defined ac-
cording to the Navot et al. [11]. Those patients experien-
cing OHSS were managed by cycle cancellation, coasting,
or freezing the embryo for future IVF cycles with or with-
out additional cabergoline (dostinex) therapy.
The ethical committee of the Faculty of Medicine
(Tehran University of Medical Sciences) approved the
study and waved the need for written informed consent.
The data was handled and analyzed anonymously.
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Independent sample T-tests and Chi square tests were
used to compare correspondingly the difference of con-
tinuous values and the prevalence of categorical vari-
ables between subjects with and without OHSS. A
binary logistic regression model (enter method) was de-
signed to study the multivariate correlation of OHSS
with age, BMI, basal biochemical indices (including
AMH), sonographic findings (follicle count), and clinical
outcomes (retrieved oocytes). Additionally, a univariate
general linear model (enter method) was employed to
adjust the effect of covariates on the association of
OHSS and AMH level. Finally, a receiver operating char-
acteristics (ROC) curve was created to classify subjects
with and without OHSS according to AMH levels. Two
different approaches were assessed to determine the op-
timal cutoff value of AMH to classify OHSS: Youden
index which is the maximum sensitivity - (1-specificity)
and the shortest distance on the ROC from the optimal
sensitivity and specificity [(1 - sensitivity)2 + (1 - specifi-
city)2] [12]. Sensitivity, specificity, positive likelihood
ratio [PLR; sensitivity / (1 - specificity)], and negative
likelihood ratio [NLR; (1 - sensitivity) / specificity] of the
cutoffs were also calculated [13]. A binary logistic re-
gression model was also designed to predict poor re-
sponse to stimulation with different variables including
AMH level. The response to stimulation was defined
poor ≤4 collected oocytes or good > 4 collected oocytes
in this model.
The AMH values were not normally distributed
(Kolmogorov-Smirnov’s P value <0.001) and were positivelyTable 1 The characteristics of the subjects with and without ovarian
Subjects without OHSS n =
Age (yrs) 32.8(0.5)
BMI (kg/m2) 24.8(0.5)
Duration of infertility (yrs) 6.1(0.5)
Duration of stimulation (days) 10.6(0.2)
Number of follicles (HCG day) 9.1(0.5)
Number of retrieved oocytes 6.9(0.5)
Basal Anti-mullerian Hormone 3.6(0.3)
Basal Luteinizing Hormone 7.6(0.5)
Basal Follicle stimulating Hormone 7.8(0.5)




Polycystic ovary syndrome 17(9.2-24.9)
Clinical pregnancy 44.3(33.9-54.7)
Data are mean or percentages and standard error from the mean or 95 % confiden
† indicates significant difference between the values of subjects with and without oskewed. For the parametric tests the square root of the
AMH values was generated and employed (Kolmogorov-
Smirnov’s P value of transferred data = 0.39).
Results
The subjects’ characteristics are shown in Table 1. Basal
AMH level as well as ovarian follicle and collected
oocytes counts but not age and BMI were higher in the
subjects with OHSS. The mean basal AMH value of the
105 studied cycles was 4.2 ng/ml [SD: 3.3, median: 3.5,
inter-quartile range: 1.4-7.0, range: 0.05-15.0]. Sixteen
patients presented with moderate or severe OHSS
(15.2 %) out of whom 4 cycles were canceled, oocytes
were collected for subsequent IVF attempts in 7 cases
(with additional dostinex therapy in one patient), ovula-
tion induction was coasted in 2 patients (with additional
dostinex therapy in one patient), and two subjects were
treated with dostinex alone. Two cases with severe
OHSS were managed in the hospital setting. Forty-two
(40 %; CI: 30.6-49.4 %) IVF/ICSI cycles led to clinical
pregnancies and 37 (35.2 %; CI: 26.1-44.4 %) live births.
The subjects with OHSS had a clinical pregnancy rate of
3/16 in the studied cycles with only 2 live births both in
subjects treated with dostinex alone. In 4 patients (25 %)
the OHSS occurred early and severely enough to prevent
oocyte collection and 2 patients, out of 89 subjects
(2.2 %), without OHSS had no oocytes yield.
Twenty-five subjects (23.8 %; CI: 15.7-32.0 %) had
PCOS with higher prevalence of OHSS (40 % vs. 7.6 %;
p < 0.001), younger age [30.5(0.7) vs. 33.3 (0.5); p =
0.005] and higher basal AMH levels [7.1(0.7) vs. 3.3(0.3);hyper-stimulation syndrome
















ce intervals in the parentheses.
varian hyper-stimulation syndrome (T-test or Chi squared test; p < 0.05).
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tically different from other patients [28(10.4-45.6) vs.
44.3(33.3-55.3); p = 0.1].
The binary logistic regression model was designed
with age, BMI, number of previous OSCs, PCOS, FSH
level, number of retrieved oocytes, and basal AMH level
(square root) as independent variables to predict the
OHSS (dependent variable). The number of retrieved
oocytes [OR: 1.3(95 CI: 1.1-1.6), Wald: 8.0, and P =
0.004] and basal AMH value [OR: 5.4 (95 CI: 1.1-27.9),
Wald: 4.1, and P = 0.04] (but not PCOS, age, and BMI)
were significant independent predicting factors of OHSS.
The square root of basal AMH levels were moderately
correlated with the number of retrieved oocytes (r = 0.5;
p < 0.001). Another model was defined with follicle
count instead of collected oocytes count (considering
significant co-linearity). In this model, in addition to
AMH level the follicle count was significantly associated
with OHSS [OR: 1.5 (95 CI: 1.1-1. 9), Wald: 8.9, and
P = 0.003]. A binary logistic regression model was de-
fined with independent variables identical to those of
the previous models excluding collected oocyte or fol-
licle counts. AMH level (square root) was the only
predictor of the response to stimulation [OR: 0.25 (95
CI: 0.11-0.59), Wald: 10.3, and P = 0.001].Fig. 1 Age adjusted anti-mullerian hormone is higher in those with conseq
polycystic ovary syndromeThe total administered gonadotropin dose (but not
total days of stimulation) correlated inversely with the
OHSS occurrence (OR for every additional 75 inter-
national unit = 0.8, CI: 0.7-0.9; p = 0.002).
After adjustment for the effect of age, BMI, and PCOS;
the AMH values were higher in the subjects with
consequent OHSS than in those without OHSS [7.7
(0.7) ng/ml vs. 4.7(0.4) ng/ml; df = 5, F (11.9) = 14.2,
eta2 = 0.1; P = 0.001]. No significant interaction effect
was detected for the presence of PCOS on the asso-
ciation of AMH levels and OHSS [F (11.9) =2.4 and
P = 0.1; Fig. 1].
AMH levels classified subjects with and without OHSS
with an area under the ROC curve (AUC) of 0.86 (0.78-
0.95; Fig. 2); the best AMH cutoff value to predict OHSS
was 6.95 ng/ml (sensitivity: 75 %, specificity: 84 %, PLR:
4.7, NLR: 0.3; Fig. 3, panel a). Patients with AMH values
higher than 6.95 ng/ml experienced a higher frequency
of OHSS (5.1 % vs. 46.2 %; OR = 9, CI: 1.3-59.7, Chi2 P
value < 0.001). In subjects without OHSS, those with
AMH values over 6.95 (n = 14) compared to those with
AMH levels below 6.95 received significantly smaller
gonadotropine doses per day [157 (17) IU vs. 197 (46);
p < 0.005] with higher collected oocytes [9.4 (1.0) vs. 6.4
(0.5); p < 0.05] and the equal follicle count [11.1 (0.7) vs.uent ovarian hyper-stimulation syndrome in patients with and without
Fig. 2 The Receiver Operating Characteristics (ROC) curves of basal anti-mullerian hormone values to predict ovarian hyper-stimulation syndrome.
AURC: Area Under the ROC Curve
Aghssa et al. Reproductive Health  (2015) 12:85 Page 5 of 88.7 (0.7); p < 0.067]. The cutoff value of AMH with the
best prediction of poor response to controlled ovarian
stimulation (oocytes ≤4) was 1.65 ng/ml with AUC of
0.8 (0.69-0.91) and sensitivity and specificity of 89 %
and 71 %, respectively (Fig. 3, panel b). A poor response
rate in those with an AMH value below and above
the cut point (1.65) was 75 % and 13.7 %, respectively
(OR = 23.8, CI: 6.0-94.1, Chi2 P value <0.001). The
cut points for detection of OHSS and poor response
were substantially the same after exclusion of subject
with PCOS (data not shown).
No significant association was found between basal
AMH level and the outcome of the IVF/ICSI procedure
(clinical pregnancy vs. failed cycle).
Discussion
Our results indicate an association between extreme
AMH levels and OHSS and poor response to controlled
ovarian stimulation independent of the effect of age,
BMI, and a history of PCOS. According to our findings,
subjects with an AMH level <1.65 (almost the lower
quartile of AMH values) are more likely to be poorresponders to ovarian stimulation (post-test probability:
75 %; OR = 23) and those with AMH levels >6.95
(almost the upper quartile) are at a higher risk for OHSS
(post-test probability: 46 %; OR = 9). With subclass ana-
lysis of the administered gonadotropin dose, we suggest
that milder ovarian stimulation in high risk patients has
no detrimental effect on the COH main outcome (re-
trieved oocyte count). Thus, we believe that based on
the proposed cut point of basal AMH levels (i.e. 6.95;
roughly the upper quartile), reduced stimulation would
be a safe and the reasonable method of preventing
OHSS and its consequences. This approach may decrease
the severe OHSS cases with its unfavorable consequences
including hospitalization and cycle cancellation [14]. After
adjustment for AMH levels, other pre-stimulation vari-
ables including age, BMI, and PCOS did not correlate with
OHSS or poor response to COH.
Our optimal cutoff value of AMH for the prediction of
OHSS is higher than the cut points suggested by previ-
ous studies (i.e. 1.6 ng/ml [15], 2.1 ng/ml [16], 3.4 ng/ml
[17], 3.5 ng/ml [18, 19] and 4.8 ng/ml [20]). Our results
are in line with the result of La Marca et al. [4] with
Fig. 3 Sensitivity, specificity, Yuden index and distance to the optimal point on the ROC curve for the basal anti-mullerian hormone levels to
predict ovarian hyper-stimulation syndrome (panel a) and poor response to the IVF cycle (panel b). Arrows indicate the most effective threshold
value of AMH (6.95 and 1.65 ng/ml for ovarian hyper-stimulation syndrome and poor response to ovarian stimulation, respectively) corresponding
to both maximum Youden index and shortest distance on the ROC curve
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cation of exaggerated responses. The threshold value of
the study by Lee et al. was numerically lower but again
it was the 75th percentile of the AMH values of the stud-
ied population. Ebner et al. [21] also reported the best
ovarian response was achieved when the basal AMH
value was between the 25th and 75th percentiles with
reduced oocyte quality of patients in the top quartile
(AMH level > 4.5 ng/ml). The cutoff point suggested by
Nardo et al. (3.5 ng/ml) is presumably the upper quartile
of non-PCOS normal responders to COH. The differ-
ences between the AMH thresholds for higher OHSS
risk noted in this study as compared to other studies
may be explained by the differences between the studied
populations (age, threshold for treatment of infertility, or
frequency of PCOS), the definition of OHSS, and the
different AMH measurement methods. Roughly - also
not limited by the remarkable difference between the
AMH readings of two older ELISA kits i.e. DSL and
Immunotech - the patients with upper quartile AMH
values are at high risk for exaggerated ovarian response[22]. Generally there is good correlation between the new
(i.e. Beckman-Coulter) and old AMH assay kits [23].
In our study 15 % of cases had moderate to severe
OHSS. Moderate OHSS is reported in 1 to 14 % of sub-
jects with less than 1 % severe OHSS cases [24]. We had
higher frequency of diagnosed OHSS compared to the
studies by Lee et al. (8 %), Nardo (10 %) and Aramvit
et al. (12 %). Nevertheless, the prevalence of severe cases
leading to hospitalization was relatively low [25]. The
risk of excessive ovarian response is a function of the
COH protocol and the health characteristics of the par-
ticipants (including age and the prevalence of PCOS).
One may expect to encounter less exaggerated responses
in the short COH protocols and in populations with
lower PCOS. The prevalence of PCOS was high among
the infertile population of this study (i.e. 23.8 %). The
prevalence of PCOS among subjects undergoing COH
varies from 4 to 22 % [17, 19, 26]. The risk of OHSS in
our study was dramatically high in patients with PCOS
(40 %), which is consistent with the study by Aramvit
et al. in which about 45 % of the PCOS subjects
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OHSS associated with AMH high levels independent of
the diagnosis of PCOS. Also after adjustment for the ef-
fect of AMH there was no correlation between PCOS
and OHSS.
The clinical pregnancy rate was comparable and rather
high in our study (40 %) as compared with the results of
Nardo et al. (24 %) [19], Kini et al. (34 %) [27], and Lee
et al. (41 %) [17]. Relatively higher pregnancy rates ac-
company higher exaggerated ovarian stimulation rates
possibly due to stronger protocols or possibly higher
prevalence of younger PCOS patients.
Our study suffers from certain flaws: above all the
OHSS was mainly diagnosed based on the decision of
the chief researcher who decided also for the future
treatment of the patients. This reduces the extend the
results could be extrapolated. The sample size of the
study was also rather small, hence the conclusion re-
garding the pregnancy rate after assisted reproduction
cycles should be interpreted with caution; however, this
result adds information regarding the ethnic group being
studied here. Also we employed long down-regulated
protocol because at the time of study antagonist agents
were unavailable to us. Lastly, since the measurement of
AMH by Gen II assay is subject to the complement
interference which may overestimate or underestimate
the actual AMH values, further studies with the use of
new protocols even in the already studied populations
are justified [28].
Conclusions
We suggest that infertile patients undergoing COH with
top and low quartile basal AMH values are at high risk
for OHSS and poor ovarian response, respectively. Re-
duced stimulation dosage in high risk subjects for OHSS
had no detrimental effect on the final outcome. Our
study indicated that AMH was a superior predictor to
traditional factors including age, BMI, and PCOS. Also
considering that AMH is available before the stimula-
tion, it is superior to the number of oocytes yielded.
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